Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 5:13 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 7,258 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: High-Risk Clear all

Conditions: Type 2 Diabetes, Glucose Metabolism Disorders, Glucose, High Blood
Interventions: Diazoxide, Placebo; Drug
Lead sponsor: Meredith Hawkins; Other
Eligibility: 21 Years to 45 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ
Interventions: Intismeran autogene, BCG; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 20
States / cities: Bakersfield, California • Los Alamitos, California • Los Angeles, California + 15 more

Conditions: Cancer
Interventions: Pedometer, Actigraph, Perturbation Treadmill; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Alzheimer Disease, Memory Loss
Interventions: Transcranial alternating current stimulation (tACS); Device
Lead sponsor: Hebrew SeniorLife; Other
Eligibility: 55 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Multiple Myeloma
Interventions: Bortezomib 1 mg/m2, Bortezomib 1.3 mg/m2, Bortezomib 1.6 mg/m2, Melphalan; Drug
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years to 76 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Sarcoma, Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma, Metastatic Bone Tumor, Bone Sarcoma
Interventions: Ascorbate; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Overweight and Obesity
Interventions: Pecan snack, Tortilla chip snack; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 20 Years to 50 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Alveolar Ridge Preservation, Tooth Extraction
Interventions: Leukocyte platelet rich fibrin plug + d-PTFE membrane, d-PTFE membrane; Biological · Device
Lead sponsor: Firas Al Yafi; Other
Eligibility: 18 Years to 80 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Breast Cancer
Interventions: Lovaza™; Drug
Lead sponsor: Carol Fabian, MD; Other
Eligibility: 25 Years to 70 Years · Female only
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Interventions: Gemtuzumab Ozogamicin; Drug
Lead sponsor: New York Medical College; Other
Eligibility: Up to 25 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2023
U.S. locations: 1
States / cities: Valhalla, New York

Conditions: Ovarian Cancer, Breast Cancer, Prostate Cancer
Interventions: LY2606368; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Brain Tumor, Central Nervous System Tumor
Interventions: lomustine, temozolomide; Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 3 Years to 21 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 206
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more

Conditions: Hypertrophic Cardiomyopathy, Coronary Artery Disease
Interventions: Observational: Arrhythmogenic Substrate; Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Invasive Bladder Cancer
Interventions: HIPEC; Procedure
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 45 Years to 85 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Multiple Myeloma
Interventions: Melphalan, Bortezomib; Drug
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 60 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2022
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Hackensack, New Jersey

Conditions: Acute Myelogenous Leukemia AML, Myelodysplastic Syndrome MDS
Interventions: Vidaza and Valproic Acid; Drug
Lead sponsor: Patrick Stiff; Other
Eligibility: 2 Years to 89 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Atherosclerosis, Cardiovascular Disease
Interventions: any statin, niacin, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 65 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Prostate Cancer
Interventions: Suramin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2008
U.S. locations: 26
States / cities: Chicago, Illinois • Urbana, Illinois • Cedar Rapids, Iowa + 19 more

Conditions: Myocardial Fibrosis
Interventions: Elucirem (Gadopiclenol); Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years and older
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Prostate Cancer
Interventions: doxercalciferol, conventional surgery; Dietary Supplement · Procedure
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 21 Years to 120 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 6
States / cities: Iowa City, Iowa • Rochester, New York • Madison, Wisconsin + 1 more

Conditions: Myelodysplastic Syndrome
Interventions: ON 01910.Na; Drug
Lead sponsor: Traws Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Stanford, California

Conditions: Dyslipidemia
Interventions: LY2484595, Atorvastatin, Simvastatin, Rosuvastatin, Placebo for LY2484595, Placebo for Statins; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 398 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 38
States / cities: Fayetteville, Arkansas • San Diego, California • Spring Valley, California + 35 more

Conditions: Abdominal Aortic Aneurysms, Thoracoabdominal Aneurysms, Pararenal Aortic Aneurysm
Interventions: Physician Modified Endograft; Device
Lead sponsor: Steven Maximus; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hypertension
Interventions: ramipril; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 6 Years to 16 Years
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 30
States / cities: Birmingham, Alabama • Los Angeles, California • Augusta, Georgia + 22 more

Search by objective public record fields.

Central Mechanisms That Regulate Glucose Metabolism in Humans

A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)

"Prescribing" Exercise to Cancer Patients At High-Risk for Falls

Home-based Brain Stimulation for Memory

Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma

Gemcitabine Plus Ascorbate for Sarcoma in Adults (Pilot)

Effects of Pecan Nut Snacks v Equicaloric Snacks on Appetite, Food Intake, Metabolism, Hormones and Biomarkers

A 14 Weeks Longitudinal Study to Investigate the Effect of Leukocyte- Platelet Rich Fibrin Plug on the Quality of the Newly Formed Bone in Ridge Preservation Procedure Following a Tooth Extraction. It is a Clinical, Radiographic and Histomorphometric Study.

Breast Cancer Risk Biomarkers in Postmenopausal Women

Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS

A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer

Temozolomide Plus Lomustine Followed by Radiation Therapy in Treating Patients With High-Grade Malignant Glioma

Hypertrophic Cardiomyopathy Pilot Study

HIPEC After Radical Cystectomy for High Risk Bladder Cancer

Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older

Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDS

High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly

Low, Intermediate, or High Dose Suramin in Treating Patients With Hormone-Refractory Prostate Cancer

High Relaxivity Contrast Agent for Cardiac MR in the Myocardial Scar Assessment

Doxercalciferol Before Surgery in Treating Localized Prostate Cancer

Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk

A Study of LY2484595 in Patients With High LDL-C or Low HDL-C

Physician-Modified Endografts for Complex Aortic Aneurysms and Thoracoabdominal Aneurysm Repair in High-Risk Patients

Treatment of Pediatric Hypertension With Altace Trial